Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131400) titled 'Clinical Study on the Use of Iparomlimab and tuvonralimab Combined with Bevacizumab and HAIC for the Conversion Therapy of Potentially Resectable Hepatocellular Carcinoma Patients' on Sept. 1.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Harbin Medical University Cancer Hospital

Condition: Potentially resectable hepatocellular carcinoma

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-09-01

Target Sample Size: Intervention group:50;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=341191

Disc...